THE WOODLANDS, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2024, and ...
Latest data shows the largest indicative borrow rate increases among liquid option names include: BHP Billiton (BHP) 14.94% +4.96, Bitfarms ...
Zacks Investment Research on MSN22h
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue EstimatesEditas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.23 per share a year ago. These figures are ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to announce Q4 earnings results on Thursday, March 6th, after market close. The consensus EPS Estimate is -$0.12 (+40.0% Y/Y) and the consensus ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback